Steven A. Toms, M.D., M.P.H., F.A.A.N.S., F.A.C.S. · 10/4/2018 · Steven A. Toms, MD, MPH,...

CURRICULUM VITAE

Date of Preparation: October 4, 2018

_________________________ SIGNATURE

Steven A. Toms, M.D., M.P.H., F.A.A.N.S., F.A.C.S. WARREN ALPERT SCHOOL OF MEDICINE AT BROWN UNIVERSITY

Professor, Departments of Neurosurgery, Medicine, and Health Policy LIFESPAN HEALTH SYSTEM

Vice Chairman, Department of Neurosurgery Director of the Brain Tumor Program

Co-Director of Molecular Neuroscience and Neuro-Oncology Research Laboratory Co-Director of CyberKnife and Gamma Knife Stereotactic Radiosurgery Program

OFFICE ADDRESS: Lifespan Health System Department of Neurosurgery 593 Eddy Street APC 6 Providence, RI 02903 OFFICE TELEPHONE: 401-793-9175 OFFICE FAX: 401-606-4012 EDUCATION:

BROWN UNIVERSITY, Providence, RI B.A. Political Science, September 1982 - May 1986 M.D. September 1985 - May 1989 THE JOHN HOPKINS UNIVERSITY SCHOOL OF PUBLIC HEALTH & HYGIENE Baltimore, MD M.P.H. July 1991 - May 1992 POSTGRADUATE TRAINING: THE MD ANDERSON CANCER CENTER Houston, TX Fellow - Neurosurgical Oncology 7/1997 - 6/1998

THE CLEVELAND CLINIC FOUNDATION Cleveland, OH Resident - Neurological Surgery 7/1992 - 7/1997

THE JOHN HOPKINS UNIVERSITY HOSPITAL Baltimore, MD Resident - Preventive Medicine 7/1991 - 6/1992

Steven A. Toms, MD, MPH, FAANS, FACS

3

THE CLEVELAND CLINIC FOUNDATION Cleveland, OH Resident - Neurological Surgery 6/1989 - 12/1990 POSTGRADUATE HONORS AND AWARDS: Compassionate Physician Award 2012-2013 Best Surgeons in America 2010 -2017 Press-Ganey Award Achieved highest level of patient satisfaction among neurosurgeons in nation 2008 Best Doctors in America 2002, 2005 2007- 2017 ROSE Award - Oregon Health & Sciences University Recognizing outstanding service excellence 2002 The Bruce Hubbard Stewart Award – The Cleveland Clinic Foundation Recognizing compassion and skill in the practice of medicine 1997 The International Center for Specialty Studies International Traveling Fellow Award The Cleveland Clinic Foundation - Recognizing outstanding resident 1997 George and Grace Crile Traveling Fellowship Award The Cleveland Clinic Foundation - Recognizing outstanding surgical resident 1997 American Association of Cancer Research Fellowship - for study in molecular biology 1994 Cleveland Clinic Neuroscience Research Day, First place, Junior Division 1994,1995 Cleveland Clinic Neuroscience Research Day, First place, Senior Division 1996 Brown University Program in Medicine Award Outstanding Performance in Medical Studies 1985 -1989 Sigma Xi, the Scientific Research Society, associate member 1989 Brown chapter of Sigma Xi award for outstanding research 1987 PROFESSIONAL LICENSES AND BOARD CERTIFICATION: Fellow, The American Association of Neurological Surgeons Fellow, The American College of Surgeons Diplomate of the National Board of Medical Examiners Gamma Knife Certification

Board Certified: American Board of Neurological Surgeons Issued: May 27, 2003 (re-certified 2013); Expiration 2023 Medical license, State of Pennsylvania Issued: 2007 Medical license, State of Rhode Island Issued: 2016


4

ACADEMIC APPOINTMENTS: WARREN ALPERT MEDICAL SCHOOL AT BROWN UNIVERSITY Providence, RI Professor of Neurological Surgery and Medicine 2016 - present Director, Neurosurgical Oncology Fellowship Program 2017 - present GEISINGER HEALTH SYSTEM Danville, PA Director, Neurosurgical Oncology Fellowship Program 2014 - 2016 Head, Neuro-oncology & Skull Base Surgery Rotations Dept. of Neurosurgery, ACGME accredited Residency Program 2012 - 2016 TEMPLE UNIVERSITY SCHOOL OF MEDICINE Philadelphia, PA Clinical Professor (adjunct), Department of Neurosurgery 3/2012 – 10/16

Medical Student Rotation Mentor 2007 – 2016

PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE Philadelphia, PA Director, Neurosurgical Residency Rotation 2007 - 2014

THE CLEVELAND CLINIC FOUNDATION Cleveland, OH Full Staff, The Brain Tumor Institute 4/2004 - 5/2007 Associate Staff, The Brain Tumor Institute 1/2003 - 3/2004 Resident Mentor, Department of Neurosurgery 2003 - 2007 OREGON HEALTH & SCIENCES UNIVERSITY Portland, OR Assistant Professor, Neurological Surgery 10/2001 -12/2002 Director, Neurosurgery VA Residency Rotation 2001 – 2002 VANDERBILT UNIVERSITY MEDICAL CENTER Nashville, TN Assistant Professor, Neurological Surgery & Otolaryngology 7/1998 – 9/2001 HOSPITAL APPOINTMENTS: BROWN UNIVERSITY / LIFESPAN HEALTH SYSTEM Providence, RI Vice Chairman, Department of Neurosurgery 10/2016 - present Director of the Brain Tumor Program Co-Director of Molecular Neuroscience and Neuro-Oncology Research Laboratory Co-Director of CyberKnife and Gamma Knife Stereotactic Radiosurgery Program GEISINGER HEALTH SYSTEM Danville, PA Associate Chief Medical Officer 3/2010 – 10/2016 Co-Director, Neuroscience Institute 6/2007 – 10/2016 (Director September 2008 – May 2009) Director, Department of Neurosurgery 6/2007 – 10/2016 THE CLEVELAND CLINIC FOUNDATION Cleveland, OH Director Section of Metastatic Disease, Brain Tumor Institute 1/2003 - 5/2007 PORTLAND VA MEDICAL CENTER Portland, OR Chief, Department of Neurological Surgery 10/2001-12/2002 OREGON HEALTH SCIENCES UNIVERSITY Portland, OR


5

Head, Section of Neurosurgical Oncology 10/2001 – 12/2002 VANDERBILT UNIVERSITY MEDICAL CENTER Nashville, TN Head, Section of Neurosurgical Oncology 07/1998 - 9/2001 Head, Skull Base Section Director, Neurosurgical Intensive Care Unit

OTHER APPOINTMENTS: EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorships: Editor, Nanoproteomics: Methods in Molecular Biology 2010 - 2012 Associate Editor in Surgical Techniques and Implantable Devices Wiley Interdiscliplinary Reviews: Nanomedicine and Nanobiotechnology 2006 - 2010

Editorial Boards:

Editorial Board, Nanomedicine 2006 – present Editorial Board, Neurological Surgery: Clinics in Surgery 2016 - present

Journal Reviews: Ad Hoc Reviewer, Neuro-oncology 2018 - present Ad Hoc Reviewer, Oncotarget 2017 - present Ad Hoc Reviewer, Journal of Surgical Oncology 2016 - present Ad Hoc Reviewer, Radiation Oncology 2016 - present

Ad Hoc Reviewer, BMC Cancer 2015 - present Ad Hoc Reviewer, PLOS One 2011 - present Ad Hoc Reviewer, Cancer 2011 - present Ad Hoc Reviewer, Journal of Clinical Oncology 2010 - present Ad Hoc Reviewer, Journal of Neuro-Oncology 2008 - present Ad Hoc Reviewer, Optical Letters 2007 - 2012 Ad Hoc Reviewer, Cleveland Clinic Journal of Medicine 2005 - 2007

OTHER APPOINTMENTS: NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

NIH Study Section - RFP SBIR Topic 266 "Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer” 2009

American Association of Neurological Surgeon Liaison to Council of State Neurosurgical Societies 2014 – 2018 Council of State Neurosurgical Societies – Ad Hoc Committee of Neurosurgical Medical Directors 2014 – 2018 Guest examiner, American Board of Neurological Surgeons 2015


6

UNIVERSITY COMMITTEES: WARREN ALPERT SCHOOL OF MEDICINE at BROWN UNIVERSITY Committee on Medical Faculty Appointments 9/2018 - present HOSPITAL COMMITTEES: VANDERBILT UNIVERSITY MEDICAL CENTER, Nashville, TN Neuro-ICU Care Committee 7/1998 - 9/2001 PORTLAND VA MEDICAL CENTER, Portland, OR Department of Surgery Director’s Committee 10/2001 - 12/2002 CLEVELAND CLINIC, Cleveland, OH Brain Tumor Board 1/2003 - 5/2007 GEISINGER HEALTH SYSTEM, Danville, PA Clinical Director, Research Executive Committee 3/2011 – 10/2016 Chairman, Pain Task Force 12/2011 - 1/2013 Co-Chairman, Senior Search Committee 7/2012 – 6/2015 Physician’s Leadership Council 9/2015 – 10/2016 LIFESPAN HEALTH SYSTEM, Providence, RI Director, Brain Tumor Board 10/2017 - present Lifespan Cancer Institute 10/2017 - present Research Advisory Committee 8/2018 - present Head, Diversity Inclusion Action Committee (Neurosurgery) 6/2018 - present MEMBERSHIPS: HONORARY AND PROFESSIONAL SOCIETIES: Fellow, American Association of Neurological Surgeon Fellow, American College of Surgeons Sigma Xi Society for Neuro-Oncology Congress of Neurological Surgeons American Association of Neurological Surgeons The Council of State Neurosurgical Societies REFEREED JOURNAL PUBLICATIONS/ORIGINAL PAPERS 1. Toms SA: Outcome predictors in the early withdrawal of life support: Issues of justice and allocation for

the severely brain injured. The Journal of Clinical Ethics 1993, 4(3):206-211. 2. Iwasaki K, Toms SA, Barnett GH, Estes ML, Gupta MK, Barna BP: Inhibitory effects of tamoxifen and

tumor necrosis factor alpha on human glioblastoma cells. Cancer Immunology, Immunotherapy: CII 1995, 40(4):228-234.

3. Kondo S, Morimura T, Barnett GH, Kondo Y, Peterson JW, Kaakaji R, Takeuchi J, Toms SA, Liu J,

Werbel B et al: The transforming activities of MDM2 in cultured neonatal rat astrocytes. Oncogene 1996, 13(8):1773-1779.


7

4. Toms SA, Hercbergs A, Liu J, Kondo S, Haqqi T, Casey G, Iwasaki K, Barnett GH, Barna BP: Antagonist effect of insulin-like growth factor I on protein kinase inhibitor-mediated apoptosis in human glioblastoma cells in association with bcl-2 and bcl-xL. Journal of Neurosurgery 1998, 88(5):884-889.

5. Toms SA, Hercbergs A, Liu J, Kondo S, Barnett GH, Casey G, Barna BP: Thyroid hormone depletion

inhibits astrocytoma proliferation via a p53-independent induction of p21 (WAF1/CIP1). Anticancer Research 1998, 18(1A):289-293.

6. Sigurdson AJ, Bondy ML, Hess KR, Toms SA, Kyritsis AP, Gu J, Wang LE, Wang X, Adatto P, Bruner

JL et al: Gamma-ray mutagen sensitivity and survival in patients with glioma. Clinical Cancer Research : an official journal of the American Association for Cancer Research 1998, 4(12):3031-3035.

7. Toms SA, Ferson DZ, Sawaya R: Basic surgical techniques in the resection of malignant gliomas.

Journal of Neuro-oncology 1999, 42(3):215-226. 8. Lin WC, Toms SA, Motamedi M, Jansen ED, Mahadevan-Jansen A: Brain tumor demarcation using

optical spectroscopy; an in vitro study. Journal of Biomedical Optics 2000, 5(2):214-220. 9. West JB, Fitzpatrick JM, Toms SA, Maurer CR, Jr., Maciunas RJ: Fiducial point placement and the

accuracy of point-based, rigid body registration. Neurosurgery 2001, 48(4):810-816; discussion 816-817. 10. Fan X, Larson TC, Jennings MT, Tulipan NB, Toms SA, Johnson MD: December 2000: 6 month old boy

with 2 week history of progressive lethargy. Brain Pathology 2001, 11(2):265-266. 11. Lin WC, Toms SA, Johnson M, Jansen ED, Mahadevan-Jansen A: In vivo brain tumor demarcation using

optical spectroscopy. Photochemistry and Photobiology 2001, 73(4):396-402. 12. Johnson MD, Jennings MT, Toms ST: Oligodendroglial ganglioglioma with anaplastic features arising

from the thalamus. Pediatric Neurosurgery 2001, 34(6):301-305. 13. Weil RJ, Toms SA, Johnson MD, Mealer A: Detection of proliferating S-phase brain tumor cells by in

situ DNA replication. Journal of Neurosurgery 2001, 95(5):833-838. 14. Lin WC, Toms SA, Jansen ED, Mahadevan-Jansen A.: Intraoperative application of optical spectroscopy

in the presence of blood. IEEE Journal of Selected Topics in Quantum Electronics 2001, 7(6):996-1003. 15. Schefter JK, Allen G, Cmelak AJ, Johnson M, Toms S, Duggan D, Blevins LS: The utility of external

beam radiation and intracystic 32P radiation in the treatment of craniopharyngiomas. Journal of Neuro-oncology 2002, 56(1):69-78.

16. Johnson MD, Woodard A, Okediji EJ, Toms SA, Allen GS: Lovastatin is a potent inhibitor of

meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase. Journal of Neuro-oncology 2002, 56(2):133-142.

17. Lin WC, Toms SA, Johnson M, Weil RJ, Mahadevan-Jansen A. “Detection of radiation injured brain

tissue using optical spectroscopy”, OSA Technical Digest (Optical Society of America), 491-493, 2002. 18. Johnson MD, Okedli E, Woodard A, Toms SA, Allen GS: Evidence for phosphatidylinositol 3-kinase-

Akt-p7S6K pathway activation and transduction of mitogenic signals by platelet-derived growth factor in meningioma cells. Journal of Neurosurgery 2002, 97(3):668-675.


8

19. Fan X, Semchyshyn TM, Mawn LA, Atkinson JB, Anderson JC, Toms SA, Johnson MD: July 2002: 66-

year-old female with a one-year history of progressive left proptosis. Brain Pathology 2003, 13(1):111-112, 117.

20. Johnson MD, Vnencak-Jones CL, Toms SA, Moots PM, Weil R: Allelic losses in oligodendroglial and

oligodendroglioma-like neoplasms: analysis using microsatellite repeats and polymerase chain reaction. Archives of Pathology & Laboratory Medicine 2003, 127(12):1573-1579.

21. Schwartz SA, Weil RJ, Johnson MD, Toms SA, Caprioli RM: Protein profiling in brain tumors using

mass spectrometry: feasibility of a new technique for the analysis of protein expression. Clinical Cancer Research: 2004, 10(3):981-987.

22. Nathoo N, Toms SA, Barnett GH, “Metastases to the Brain: Current Management

Perspectives”, Expert Review of Neurotherapeutics 4: 633-640, 2004. 23. Nathoo N, Chahlavi A, Barnett GH, Toms SA: Pathobiology of brain metastases. Journal of Clinical

Pathology 2005, 58(3):237-242. 24. Quan AL, Barnett GH, Lee SY, Vogelbaum MA, Toms SA, Staugaitis SM, Prayson RA, Peereboom DM,

Stevens GH, Cohen BH et al: Epidermal growth factor receptor amplification does not have prognostic significance in patients with glioblastoma multiforme. International Journal of Radiation Oncology, Biology, Physics 2005, 63(3):695-703.

25. Toms SA, Lin WC, Weil RJ, Johnson MD, Jansen ED, Mahadevan-Jansen A: Intraoperative optical

spectroscopy identifies infiltrating glioma margins with high sensitivity. Neurosurgery 2005, 57(4 Suppl):382-391; discussion 382-391.

26. Lin WC, Mahadevan-Jansen A, Johnson MD, Weil RJ, Toms SA: In vivo optical spectroscopy detects

radiation damage in brain tissue. Neurosurgery 2005, 57(3):518-525; discussion 518-525. 27. Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD, Caprioli RM:

Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Research 2005, 65(17):7674-7681.

28. Toms SA, Johnson M: “Mitogenic Mitogenic signal transduction pathways in meningiomas: novel

targets for meningioma chemotherapy? Journal of Neuropathology and Experimental Neurology 2005, 64(12):1029-1036.

29. Toms SA, Konrad PE, Lin WC, Weil RJ: Neuro-oncological applications of optical spectroscopy.

Technology in Cancer Research & Treatment 2006, 5(3):231-238. 30. Chao ST, Barnett GH, Liu SW, Reuther AM, Toms SA, Vogelbaum MA, Videtic GM, Suh JH: Five-year

survivors of brain metastases: a single-institution report of 32 patients. International Journal of Radiation Oncology, Biology, Physics 2006, 66(3):801-809.

31 Tendulkar RD, Liu SW, Barnett GH, Vogelbaum MA, Toms SA, Jin T, Suh JH: RPA classification has

prognostic significance for surgically resected single brain metastasis. International Journal of Radiation Oncology, Biology, Physics 2006, 66(3):810-817.


9

32. Popescu MA, Toms SA: In vivo optical imaging using quantum dots for the management of brain tumors. Expert Review of Molecular Diagnostics 2006, 6(6):879-890.

33. Muhammad O, Popescu A, Toms SA: Macrophage-mediated colocalization of quantum dots in

experimental glioma. Methods in Molecular Biology 2007, 374:161-171. 34. Jackson H, Muhammad O, Daneshvar H, Nelms J, Popescu A, Vogelbaum MA, Bruchez M, Toms SA:

Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery 2007, 60(3):524-529; discussion 529-530.

35. Gopan T, Toms SA, Prayson RA, Suh JH, Hamrahian AH, Weil RJ: Symptomatic pituitary metastases

from renal cell carcinoma. Pituitary 2007, 10(3):251-259. 36. Gonzalez-Martinez JA, Bingaman WE, Toms SA, Najm IM: Neurogenesis in the postnatal human

epileptic brain. Journal of Neurosurgery 2007, 107(3):628-635. 37. Toms SA, Suh JH, Weil RJ: Choroid plexus metastasis. Urology 2007, 70(2):370-371. 38. Marko NF, Weil RJ, Toms SA: Nanotechnology in proteomics. Expert Review of Proteomics 2007,

4(5):617-626. 39. Johnson MD, Sade B, Milano MT, Lee JH, Toms SA: New prospects for management and treatment of

inoperable and recurrent skull base meningiomas. Journal of Neuro-oncology 2008, 86(1):109-122. 40. Kim SH, Chao ST, Toms SA, Vogelbaum MA, Barnett GH, Suh JH, Weil RJ: Stereotactic radiosurgical

treatment of parenchymal brain metastases from prostate adenocarcinoma. Surgical Neurology 2008, 69(6):641-646; discussion 646.

41. Toms SA, Weil RJ, Gupta A, Boulis NM, Prayson R, Lang FF: Clinical problem-solving: island intruder.

Neurosurgery 2008, 62(4):920-928; discussion 928-929. 42. Daneshvar H, Nelms J, Muhammad O, Jackson H, Tkach J, Davros W, Peterson T, Vogelbaum MA,

Bruchez MP, Toms SA: Imaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots. Nanomedicine 2008, 3(1):21-29.

43. Marko NF, Toms SA, Barnett GH, Weil R: Genomic expression patterns distinguish long-term from

short-term glioblastoma survivors: a preliminary feasibility study. Genomics 2008, 91(5):395-406. 44. Kim SH, Weil RJ, Chao ST, Toms SA, Angelov L, Vogelbaum MA, Suh JH, Barnett GH: Stereotactic

radiosurgical treatment of brain metastases in older patients. Cancer 2008, 113(4):834-840. 45. Marko NF, Angelov L, Toms SA, Suh JH, Chao ST, Vogelbaum MA, Barnett GH, Weil RJ: Stereotactic

radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases. World Neurosurgery 2010, 73(3):186-193; discussion e129. PMID: 20860956

46. Peereboom DM, Shepard DR, Ahluwalia MS, Brewer CJ, Agarwal N, Stevens GH, Suh JH, Toms SA,

Vogelbaum MA, Weil RJ et al: Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. Journal of Neuro-oncology 2010, 98(1):93-99. PMID: 19960228


10

47. Grosu ID, Toms MA, Toms SA: Nanoimaging and neurological surgery. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology 2010, 2(6):601-617. PMID: 20669333

48. Beasley KD, Toms SA, “The molecular pathobiology of metastasis to the brain: a review”, Neurosurg Clin N Am. Jan;22(1):7-14, 2011. 49. Siomin V, Lin JL, Marko NF, Barnett GH, Toms SA, Chao ST, Angelov L, Vogelbaum MA, Navaratne

K, Suh JH et al: Stereotactic radiosurgical treatment of brain metastases to the choroid plexus. International Journal of Radiation Oncology, Biology, Physics 2011, 80(4):1134-1142. PMID: 21683888

50. Bedi AD, Toms SA, Dehdashti AR: Use of Hemostatic Matrix for Hemostasis of the Cavernous Sinus

during Endoscopic Endonasal Pituitary and Suprasellar Tumor Surgery. Skull Base 2011, 21(3):189-192. PMID: 22451824

51. Marko NF, Suh JH, Chao ST, Barnett GH, Vogelbaum MA, Toms S, Weil RJ, Angelov L: Gamma knife

stereotactic radiosurgery for the management of incidentally-identified brain metastasis from non-small cell lung cancer. Journal of Neuro-oncology 2011, 104(3):817-824.

52. Rahmathulla G, Toms SA, Weil RJ: The molecular biology of brain metastasis. Journal of Oncology

2012, 2012:723541, 16pages. PMID:22481931 53. Timmons SD, Toms SA: Comparative effectiveness research in neurotrauma. Neurosurgical Focus 2012,

33(1):E3. 54. Slotkin JR, Casale AS, Steele GD, Jr., Toms SA: Reengineering acute episodic and chronic care delivery:

the Geisinger Health System experience. Neurosurgical Focus 2012, 33(1):E16. PMID: 22746233 55. Gharavi MH, Wu HH, Toms SA: High fluorodeoxyglucose ((18)F)PET-uptake lymph nodes in a patient

with chordoma: Tumor metastasis or sarcoidosis? The American Journal of Case Reports 2013, 14:373-375. PMID: 24086794

56. Rivkin M, Toms A, Bronov O, Lacroix M, Wu HH, Toms SA: Cerebellopontine angle chondroid

meningioma apoplexy complicating a third trimester pregnancy: case report and review of the literature. Journal of Clinical Gynecology & Obstetrics 2013, 2(2):84-89.

57. Turner SG, Gergel T, Wu H, Lacroix M, Toms SA: The effect of field strength on glioblastoma

multiforme response in patients treated with the NovoTTF-100A system. World Journal of Surgical Oncology 2014, 12:162. PMID: 24884522

58. Svokos KA, Salhia B, Toms SA. Molecular Biology of Brain Metastasis. International Journal of

Molecular Science 15(6): 9519 - 30, 2014, PMID: 24879524 59. Weil RJ, Mavinkurve GG, Chao ST, Vogelbaum MA, Suh JH, Kolar M, Toms SA: Intraoperative

radiotherapy to treat newly-diagnosed solitary brain metastasis: initial experience and long-term outcomes. Journal of Neurosurgery 122(4): 825 – 32, 2015. PMID: 25614945

60. Hill-Felberg S, Wu HH, Toms SA, Dehdashti, A: Notch Receptor Expression in Human Brain

Arteriovenous Malformations. Journal of Cellular and Molecular Medicine. Aug 19(8):1986-93, 2015 PMID: 25846406


11

61. Stupp R, Tailibert S, Kanner A, Kesari S, Steinberg D, Toms SA, Taylor L, Lieberman F, Silvani A, Fink K, Barnett G, Zhu J, Henson JW, Engelhard H, Chen T, Tran D, Sroubek J, Tran N, Hottinger A, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi M, Ram Z. A Phase 3 Randomized Controlled Trial Comparing Tumor-Treating Fields Therapy Plus Temozolomide to Temozolomide Alone Maintenance Therapy for Newly Diagnosed Glioblastoma, JAMA, 2015 Dec15, 314(23): 2535-43, 2015 PMID: 26670971.

62. Slotkin JR, Ness JK, Snyder KM, Skiles AA, Woodard EJ, O’Shea T, Layer RT, Aimetti AA, Toms SA,

Langer R, Tapinos N. Sustained local release of methylprednisolone from a thiol-acrylate poly(ethylene glycol) hydrogel for treating chronic compressive radicular pain, Spine (Phila Pa 1976), Apr 41(8): E441-8, 2016. PMID: 26630427

63. Kimbason T, Turner SG, Kazmi SA, Fourgas E, Gergel T, Belles L, Whitmire A, Lacroix M, Toms SA.

Malignant Glioma with Primitive Neuroectodermal Components: Clinical and Pathologic Features with Treatment Modalities of Five Cases. J Exp Clin Path, in press.

64. Toms SA. Tumor Treating Fields and Other Technological Advances in the Treatment of Cancer. Clin Adv Hematol Oncol, Nov 13 (11 Suppl 11) 3 -7, 2015.

65. Wong ET, Toms SA, Ahluwalia MS. Clinical Use of Tumor Treating Fields: Discussion. Clin Adv

Hematol Oncol, Nov 13 (11 Suppl 11) 16 - 17, 2015. 66. Kershenovich A, Toms SA. The Acetazolamide Challenge: A Tool for Surgical Decision –making and

Predicting Surgical Outcome in Patients with Arachnoid Cysts. J of Neurol Surg-A, Jan 78(1): 33 – 41, 2017. PMID: 27415592.

67. Ahmad M, Jacobs D, Jaramillo C, Wu H, Wolk DM, Kazmi SAJ, Toms S. Cladophialophora bantiana:

A rare intracerebral fungal abscess. Case series and review of literature. Surg J, 3: e62-e68, 2017 PMID: 28825023.

68. Slotkin JR, Ross OA, Newman ED, Comrey J, Watson V, Lee RV, Brosious MM, Gerrity G, Davis SM,

Paul J, Miller EL, Feinberg DT, Toms SA. Episode-based payment and direct employer purchasing of healthcare services: Recent bundled payment innovations and the Geisinger Health System experience. Neurosurgery. 2017 Apr 1 80(4S): S50-58. PMID: 28375499 .

69. Toms MC, Gasteiger MG, Lal S, Bollinger B, Toms SA. Intranuclear Ophthalmoplegia Complicating the

Resection of a Fourth Ventricular Neuroenteric Cyst. J Neurol Surg A Cent Eur Neurosurg, in press. 70. Weston C, Klobusicky J, Weston J, Connor J, Toms SA, Marko NF. Aberrations in Iron Regulatory

Gene Signature are Associated with Decreased Survival in Low-Grade Glioma, PLOS One, 2016 Nov 29; 11(11): e0166593 PMID: 27898674.

71. Konakondla S, Toms SA. Cerebral connectivity and malignant gliomas: Evolving concepts of

eloquent brain in surgery for glioma, AIMS Medical Science, in press. 72. Toms SA, Tapinos N. Recent Advances in the Treatment of Gliomas - Comprehensive Brain Tumor

Center, R I J Med, 2017 Jun 1: 100 (6): 43 – 46. PMID: 28564669. 73. Müller-Greven GM, Carlin C , Burgett M , Ahluwalia MS , Lauko A , Nowacki AS , Herting CJ, Qadan

MA , Bredel M , Toms SA , Lathia JD , Hambardzumyan D , Sarkaria JN , Hamerlik P, Gladson GL.


12

Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival, Clin Ca Res , 2017 Nov 15;23(22):7059-7071 PMID: 28912141.

74. Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia M,

Fink K, Salmaggi A, Lieberman F, Zhu J-J, Stragliotto G, Tran D, Brem S, Hottinger AF, Kirson ED, Weinberg U, Kim C-Y, Paek S-H, Nicholas G, Escuder JB, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide versus Maintenance Temozolomide Alone in Patients withGlioblastoma: A Randomized Clinical Trial, JAMA. 2017 Dec 19;318(23):2306-2316. PMID: 29260225

75. Taphoorn MJB, Dirven L, Kanner A, Lavy-Shahaf G, Weinberg U, Taillibert S, Toms SA, Honnorat J,

Chen T, Sroubek J, David C, Idbaih A, Easaw J, Kim C-Y, Escuder JB, Hottinger A, Kew Y, Roth P, Desai R, Villano J, Kirson ED, Ram Z, Stupp R. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology, 2018 Apr 1 4(4): 495 - 504.

76. Bayer AD, Blum AS, Asaad WF, Roth J, Toms SA, Deck GM. Fighting Fire with Fire: Surgical Options

for Patients with Drug-Resistant Epilepsy. R I Med J (2013). 2018 Mar 1;101(2):37-40. 77. Magouliotis DE, Asprodini EK, Svokos KA, Tasiopoulou VS, Svokos AA, Toms SA. Tumor-treating

fields as a fourth treating modality for glioblastoma: A meta-analysis, Acta Neurochirgia, 2018, Jun 160(6): 1167 - 1174.

78. Syed S, Karambizi DI, Baker A, Groh DM, Toms SA. Case Report: A Comparative Report on

Intracranial Tumor-to-Tumor Metastasis and Collision Tumors, World Neurosurgery, 2018,Aug. 116: 454 – 463.

79. Menger R, Pennicooke B, Barnes T, Fouke S, Kissel P, Origitano T, Rak R, Zusman E., Cozzens J.

Grande A, Toms S, Webb S and Taylor SL. Commentary: Impact of Hospital and Health System Mergers and Acquisitions on the Practicing Neurosurgeon: Survey and Analysis from the Council of State Neurosurgical Societies Medical Director’s Ad-Hoc Representative Section. Neurosurgery 2018, Jun 1 82(6): 157 – 163..

80. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S,

D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.. First Results on Survival from a Large Phase 3 Clinical Trial of an Autologous Dendritic Cell Vaccine in Newly Diagnosed Glioblastoma, Journal of Translational Medicine, 2018, May 29 16(1): 142.

81. Karambizi D, Tapinos N, Toms SA. RNA Based Epigenetic Regulation of Glioblastoma, JSM Brain

Science, 2018 3(1): 1017. 82. Stefan S, Jeong K-S, Plucha C, Tapinos N, Toms SA, Lee J. Determination of Confocal Plane and

Curved Focal Plane of OCT Mapping of Attenuation Coefficient. Biomedical Optics Express 2018 Oct. 9(10): 5084 – 5099.


13

83. Snyder K, Zepecki J, Ness J, Toms SA, Sarkar A, Tapinos N. Insights into the regulation of human glioma stem cell migration through a locally transmitted Lck pathway. Oncogene, 2018, in press.

BOOKS EDITED 1. Weil RJ and Toms SA (ed.) Methods in Molecular Biology: Nanoproteomics, Humana Press, Springer

Publishing Group, New York, NY, 2011. BOOKS, CHAPTERS, COMMENTS, and REVIEWS 1. Toms SA, Chyatte D. Cerebral venous thrombosis. Primer on Cerebrovascular Disease. Welch M, Caplan

L, Reis D, Siesjö, Weir B (ed.). Academic Press, San Diego, CA, pp. 528-32, 1997. 2. Toms SA. Tumor suppressor genes and the genesis of brain tumors. Youman’s Neurological Surgery.

Winn HR (ed.). W.B. Saunders and Co, Philadelphia, PA, pp. 739-47, 2004. 3. Moulder S, Johnson D, Toms SA. Metastatic breast cancer, intracranial metastases: current management

strategies. Sawaya R (ed.). Futura Publishing Co, Armonk, NY, pp. 221-44, 2004. 4. Mason A, Toms SA. Hercbergs A. Biological Response Modifiers, in High Grade Gliomas. Barnett GH

(ed.). Humana Press, Totowa, NJ, pp. 405-17, 2006. 5. Ugokwe K, Toms SA. Renal cell carcinoma brain metastases, in Clinical Management of Renal Tumors.

Novick A and Bukowski R (ed.). Human Press, Totowo, NJ, pp. 481-96, 2008.

6. Moulder S, Johnson D.H, Toms SA. Current management strategies in intracranial breast cancer metastasis. In Intracranial Metastases: Current Management Strategies. Sawaya R (ed.). Blackwell Publishing, Inc., Malden, MA, USA. ch13, 2008.

7. Stofko DL, Weil RJ, Toms SA. Surgery for Brain Metastasis. In: Central Nervous System Metastasis, the

Biological Basis and Clinical Considerations, Cancer Metastasis - Biology and Treatment. Volume 18. Palmieri D (ed.). Springer Publishing Company, New York, NY. pp. 109-132, 2012 (Chapter 7).

8. Moore B, Toms SA. Applications of nanotechnology to diseases of the spine. In The Textbook of

Nanoneuroscience and Nanoneurosurgery. Heiss J D and Kateb B (ed.). Taylor & Francis Group, New York, NY, pp. 351-360, 2013 (ch.24).

9. Lal S, Toms SA. Pathobiology of brain metastases: molecular mechanism. In: Brain metastases from

primary cancers. Hayat, Eric (ed.) Elsevier/Academic Press 2015 (ch.6). 10. Svokos K, Toms SA. Editorial: “Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in

TRAF7, KLF4, AKT1, and SMO” by Clark et al., in CNS Essential Papers in Neurosurgery, edited by Bendok B, Ghogawala Z, Tecle N, Ragel B, Asthagiri A, Resnick D, CNS, September 2014.

11. Turner SG, Ahmad, M, Toms SA. Mechanisms of Glioma Cell Invasion. In Neuro-oncology, In Tech

Rijeka, Croatia, 2016.


14

12. Ahmad, M, Toms SA. Current Trends in High Grade Gliomas. In Neuro-oncology, In Tech Rijeka, Croatia, 2016.

EDITORIALS, LETTERS TO EDITOR, OTHER 1. Toms SA. Dannenberg AL. The adult health advisor, software review. JAMA 267(6): 871, 1992.

2. Toms SA. Evaluation of a program to prevent head and spinal cord injuries: A comparison between middle

and high school. Neurosurgery 32(5):879, 1993. 3. Toms SA, Frank J. Cerebrospinal fluid creatine kinase BB isoenzyme activity and neurologic prognosis

after cardiac arrest. Neurology 50(3):830-831, 1998. 4. Chao ST, Toms SA, Suh JH. Peer Viewpoint: Brain Metastasis. Journal of Supportive Onocology 2(5):10-

11, 2004. 5. Ford PJ, DeMarco JP, Toms SA. Putting a face on the definition of surgical success: ethics and

mismatched expectations. Clinical Oncology News 2(5):1, 45, 2007. 6. Lacroix M, Toms SA. Maximum Safe Resection of Glioblastoma. Journal of Clinical Oncology.

32(8):727-728, 2014. 7. Svokos KA, Toms, SA. Editorial: Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in

TRAF7, KLF4, AKT1, and SMO by Clark VE et al. Science, 339: 1077-1080, 2013.

8. Stupp R, Toms SA, Kesari K. Treatment for Patients with Newly Diagnosed Glioblastoma – Reply. JAMA. 315(21): 2348-9, 2016.

NON-REFEREED JOURNAL PUBLICATIONS/ORIGINAL PAPERS 1. Lin W-C, Toms SA, Jansen ED, Mahadevan-Jansen, A. Spectroscopic-guided brain tumor resection. Proceedings of SPIE 3911:130-136, 2000. 2. Toms SA, Daneshvar H, Muhammed O, Jackson J, Nelms J, Vogelbaum MA, Bruchez M. Optical

Detection of brain tumors using quantum dots. Proceedings of SPIE 6009:60090S1-60090S10, 2005. 3. Toms SA, Muhammad O, Jackson H, Lin, W-C. Decline in NAD(P)H autofluorescence precedes apoptotic cell death from chemotherapy. Proceedings of SPIE 6009:60090Q1-60090Q10, 2005. 4. Toms SA. Development of quantum dots for use in glioma imaging and surgical navigation. Proceedings

of SPIE 6009:60090B1-60090B12, 2005. PEER REVIEWED VIDEO EDUCATIONAL PRODUCTS (Video, Syllabi, or Other Teaching/Educational Materials) 1. Toms SA, Video presentation: “Surgical resection of brain metastasis”, Congress of Neurological

Surgeons, October, 2005.

2. Toms SA, Video teaching material. “Surgical resection of brain metastasis”, for Surgical Masters Video Conference at Congress of Neurosurgery October, 2006.


15

REFEREED JOURNAL PUBLICATIONS/ORIGINAL PAPERS (SUBMITTED) 1 Hill-Felberg S, Smink T, Toms SA. Tumor Necrosis factor receptor switch on brain endothelial cells

following TNF-alpha exposure, submitted to Journal of Neuroinflammation, 2017 2 Martinez-Moreno M, O’Shea TM, Arner E, Toms SA, Langer R, Sarkar A, Tapinos N. Attracting

migrating human glioblastoma cells back to the site of tumor resection using an in situ curing hydrogel releasing Lipocalin-2. Submitted to Cancer Research, 2017

3 Legendre C, Johnson KN, Gooden GC, Martinez RA, Kiefer J, Bernstein M, Glen J, Gorgol L, Hinek A,

Toms SA, Salhia. Human mesodermal-derived CNS Metastasis-Associated Stromal Cells Trigger a Fibrotic Response and Limit Tumor Growth, revision submitted to Oncogene, 2018.

4 Koffer P, Katipally R, Savir G, Rava P, Toms SA, Cielo D, Kinsella T, Dipetrillo T, Wazer D,

Hepel J. Local Control and Toxicity in Single-fraction and Fractionated Stereotactic Radiosurgery in the Treatment of Brain Metastases: A Case-Matched Analysis, submitted to World Neurosurgery, 2018

5 Seddon JE, Jayarao M, Donahue JE, Toms SA. Brain Metastasis Secondary to Hepatoid Adenocarcinoma

of the Lung, submitted to BMJ Case Reports, 2018 6. Tew BY, Legendre C, Triche Jr T, Gooden GC, Johnson K, Martinez RA, Pierobon M, Petricoin EF,

O’Shaughnessy J, Osborne C, Schroeder MA, Ma DJ, Bernstein M, Sarkaria JN, Toms SA, Salhia B. Development and characterization of patient derived xenografts from central nervous system metastasis reveal minor clone expansion linked with aggressive tumor behavior. Submitted to Nature Medicine, 2018.

7. Zepecki JP, Fajardo E, Snyder K, Guetta C, Sarkar A, Fiser A, Toms SA, Tapinos N. Loss of m6A RNA

methylation during glioma stem cell differentiation is regulated by miRNAs and promotes translation efficiency. Submitted to Nature, 2018.

8. Ram Z, Kim CY, Nicholas G Toms SA., on behalf of the EF-14 Investigators. Increased compliance with

Tumor Treating Fields (TTFields) therapy is prognostic for improved survival in the treatment of glioblastoma: A subgroup analysis of the EF-14 Phase III trial. Submitted to Journal of Neuro-Oncology, 2018.

REFEREED JOURNAL PUBLICATIONS/ORIGINAL PAPERS (IN PREPARATION) 1. Tin P, Toms SA. Development of Fiber-optic Biopsy Tools for the In Vivo Localization of Fluorescent Nanoparticles. 2. Tin P, Dumitrieau A, Grosu D, Toms SA. Evaluation of Fiber-optic Biopsy Tools for Accurate In Vivo Localization of Nanoparticulate Fluorescent Probes in Experimental Brain Tumors. 3. Bolinger BD, Toms SA. 2-Octyl Cyanoacrylate reduces the incidence of postoperative cerebrospinal fluid

leak following subdural EEG array implantation: a technical note.


16

4. Slotkin JR, Burke GF, Andreychik DA, Hess WF, McKinley KE, Lacroix M, Marko N, Toms SA. ProvenCare® Lumbar Spine: A Care Pathway for Improving Outcomes in Lumbar Spinal Fusion Surgery

5. Slotkin JR, Burke GF, Andreychik DA, Hess WF, McKinley KE, Lacroix M, Toms SA Marko N. ProvenCare® Lumbar Spine: Pain Management Paradigm Decreases Narcotic Usage and Improves Patient Outcomes in Lumbar Spinal Fusion Surgery

INVITED LECTURES/WORKSHOPS/PRESENTATIONS: International 1. "Nanotechnology in Surgical Navigation and Guidance", 21st Congress of the Society for Medical

Innovation and Technology, Sinaia, Romania, October, 2009. 2. “The Role of Tumor Treating Fields in Glioblastoma Multiforme”, Japanese Society for Neurooncology,

Kyoto, Japan, December, 2015 3. “Experience with Tumor Treating Fields in Daily Clinical Practice”, European Association of Neuro-

oncology, Mannheim, Germany, October, 2016.

National 1. “Apoptosis in glioblastoma: Lessons from the laboratory and implications for therapy”, the Brigham and

Women’s / Children’s Hospital neurosurgical grand rounds, January, 1996. 2. “Apoptosis and its importance for the clinical neuroscientist”, The University of California - Davis,

neuroscience grand rounds, December, 1997. 3. “The treatment of glioblastoma: Lessons from the laboratory and implications for therapy”, University of

Texas - San Antonio, neurology/neurosurgery grand rounds, January, 1998.

4. “The neurosurgeon’s role in the treatment of cerebral metastases”, Vanderbilt University Medical Center, neurosurgery grand rounds, February, 1998.

5. “Surgical Resection of Brain Metastasis: Basic and Special Techniques”, Congress of Neurological Surgeons, October, 2004.

6. “Quantum dots detect malignant glioma”, Cambridge Healthtech Institute's 6th Annual Targeted Nanodelivery for Therapeutics and Molecular Imaging, August 2005. 7. “Surgical Resection of Brain Metastasis: Basic and Special Techniques”, Congress of Neurological Surgeons, October, 2005. 8. “Quantum dots detect malignant glioma”, OpticsEast, October, 2005 9. “Quantum Dots are phagocytized by macrophages and detect experimental malignant glioma”, International Association for Nanotechnology, November, 2005. 10. "Nanoparticulates in Surgical Navigation and Guidance", Geisinger Health System, Surgery Grand

Rounds, December, 2008. 11. "Nanotechnology in Spinal Surgery: Nanoscale Imaging and Scaffolding", 6th Annual World Congress for Brain Mapping and Image-Guided Therapy, Boston, August, 2009.


17

12. “Surgical Resection of Brain Metastasis: The Role of Histology in Treatment”, Congress of Neurological Surgeons, New Orleans, October, 2009. 13. “The Role of Advanced Practitioners in a Large Private Hospital Setting", Congress of Neurological

Surgeons, New Orleans, October, 2009. 14. “Surgical Treatment for Seizure Disorders: Role for Awake Surgery”, American College of Osteopathic

Surgeons, Atlanta, GA, September, 2011 15. “Current Treatment Strategies for Gliomas”, American College of Osteopathic Surgeons, Atlanta, GA,

September, 2011 16. “The Biology of Brain Metastasis”, 1st International Symposium on the Long -Term Control of

Metastases to the Brain and Spine”, Cleveland, OH, September, 2011 17. “Evidence-Based Role for Surgery in Brain Metastasis”, Congress of Neurological Surgeons,

Washington, DC, October, 2011 18. “Intraoperative Surgical Adjuncts for Visualizing Tumor”, Society for Neuro-Oncology, Orange County,

CA, November, 2011 19. “Regional Delivery of Chemotherapy in Cancer: Potential Clinical Opportunities and Models for

Investigation”, Langer Summit, July 2012 20. “Evidence-Based Role for Surgery in Brain Metastasis”, Congress of Neurological Surgeons, Chicago,

IL, October, 2012 21. “Management of Neurosurgical Practices: Large Group Models and the Impact of the Accountable Care

Act”, American Association of Neurological Surgeons, New Orleans, LA, April, 2013 22. “Challenges in the Management of Insular Gliomas”, Neurosurgery Grand Rounds, University of

Rochester Medical Center, May 2013 23. “The Impact of the Accountable Care Act for Neuroscience Centers: Lessons from the Geisigner

Experience”, Neuroscience Grand Rounds, University of Rochester Medical Center, May 2013 24. “Developing a Neuroscience Center”, Congress of Neurological Surgeons, September, 2013 25. “New Frontiers for Neurosurgeons in the Era of the Accountable Care Act: The Geisinger Experience”,

Council of State Neurosurgical Societies, April, 2014 26. “Management of Neurosurgical Practices: Large Group Models and the Impact of the Accountable Care

Act”, American Association of Neurological Surgeons, San Francisco, CA, April, 2014 27. “Building a Neuroscience Center”, Congress of Neurological Surgeons, October, 2014 28. “Role of Neurosurgery in ACO”, Congress of Neurological Surgeons, October, 2014 29. “Building a Neuroscience Center”, Congress of Neurosurgery, September, 2015 30. “Your Margin: What Do Neurosurgeons Bring to the Table”, Congress of Neurosurgery, Sept, 2015


18

31. “Mechanisms of Brain Metastasis” 5th International Symposium on the Long -Term Control of Metastases to the Brain and Spine”, Las Vegas, NV, November, 2015 32. “Optune: A Milestone in the Treatment of Glioblastoma”, Society for Neurooncology, San Antonio, November, 2015 33. “Update on Glioblastoma: Laboratory Insights and Clinical Trials”, Neurosurgery Grand Rounds, Brown University, May, 2016 34. “FAQs and Best Practices in the Management of Glioblastoma: Clinical Decision Making in the Newly Diagnosed Patient”, Society for Neuro-oncology, Scottsdale, AZ, November 2016. 35. “Mechanisms of Brain Metastasis”, 7th International Symposium on the Long -Term Control of Metastases to the Brain and Spine”, Las Vegas, NV, October, 2017 Regional 1. “Biology of metastatic disease”, 6th Neuro-oncology Update 2004, January, 2004.

2. “Optical Imaging in Neuro-Oncology: New Techniques and their Applications”, 7th Neuro-oncology Update 2005, January, 2005.

3. “Development of Surgical Systems for the Detection of Optical Nanoparticles”, Carnegie Mellon University, December, 2006. 4. “Intraoperative Radiotherapy for Brain Metastasis”, 1st International Symposium for Brain and Body

Stereotactic Radiotherapy”, February 2006.

5. “Point Counterpoint: Surgery for Low Grade Insular Gliomas”, 9th Neuro-oncology Update 2007, March, 2007.

6. “Surgery and Mapping Techniques for Gliomas”, 9th Neuro-oncology Update 2007, March, 2007.

7. “Surgery for Spinal Metastasis”, 9th Neuro-oncology Update 2007, March, 2007. 8. “Biology of Brain Metastasis”, Neuro-Oncology 2009: Current Concepts, Cleveland, September, 2009. 9. “Controversies in the management of Low Grade Gliomas: The Case for Aggressive Surgical Resection”,

Neuro-Oncology 2009: Current Concepts, Cleveland, September, 2009. 10. “The Role of Nanotechnology in Neurological Surgery”, Neurosurgery Grand Rounds - Visiting

Professor, Alleghany General Hospital, May 2012 11. “Development of Keystone Neuro-Oncology Network”, Penn State – Hershey Medical Center, June 2012 12. “The Future of Neurosciences in the Era of the Accountable Care Act: How Specialists Can Adopt to

Pay for Performance and Population Management”, Inova Health System, October, 2015 13. “The Neurosurgeon Under the Knife”, Pennsylvania State Neurosurgical Society, July, 2016.


19

14. “Applications of Advanced Optics and Nanotechnology in Gliomas”, Clinical Neuroscience Grand Rounds, Yale School of Medicine, February, 2017.

Local 1. “Tamoxifen induces apoptosis despite a p53 mutation in WITG3, a human glioblastoma cell line”, Ohio

State Neurosurgical Society annual meeting, October, 1994. 2. “Apoptosis in epilepsy: Laboratory correlates and theoretical considerations”, The Cleveland Clinic

Foundation, epilepsy grand rounds, March, 1996.

3. “Advances in glioma treatment: From molecular diagnostics to molecular-based therapeutics”, Oregon Health Science University, Oncology grand rounds, February, 2001.

4. "The role of the neurosurgeon in systemic cancer", Cleveland Clinic Foundation, Neurosurgery grand rounds, June, 2002.

5. “Multidisciplinary Management of Brain Metastases: 2003”, Oncology Grand Rounds, Cleveland Clinic Foundation, January , 2003.

6. “Beyond Whole Brain Radiotherapy: Evolution of the Treatment of Brain Metastases”, Neurological Surgery Grand Rounds, Cleveland Clinic Foundation, January, 2003

7. “Intraoperative spectroscopy”, 2nd Biennial Cleveland Clinic International Summit for Finding the Cure for Glioblastoma, June, 2003.

8. “Quantum Dots in Primary Brain Tumor (Glioma) Surgery”, Nanomedicine Summit, Cleveland Clinic Foundation, October, 2004.

9. “Pediatric Brain Tumors”, Cleveland Clinic Foundation, Department of Neurosurgery Grand Rounds, January, 2006.

10.“The Role of the Neurosurgeon in the Treatment of Cancer”, Geisinger Health System, Neurosciences Grand Rounds, April, 2007.

11. "Pediatric Brain Tumors", Geisinger Health System, Pediatric Grand Rounds, September, 2007.

12. "Stereotactic Radiosurgery for Brain and Spinal Tumors", Dubois Health Center, Grand Rounds, October, 2008.

13. “Intraoperative Surgical Adjuncts for Visualizing Tumor: Nanoparticles”, Bucknell University, April, 2013

14. “Treatment of Glioblastoma: Maximal Safe Resection and Novel Clinical Trials”, Reading Hospital Tumor Board, February, 2014


20

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: A. Active

Peer Review Title: Trans-nasal delivery of chemotherapy to glioblastoma using

magnetic nanoparticles and magnetic focusing Source: NIH STTR Role: Principal Investigator Dates: June 1, 2017 – December 30, 2018 Direct funds: $224,987

Title: Development of Surface Enhanced Resonance Raman Spectroscopy Nanoprobes to IL13R2α

Source: Brown University Advanced -CTR Role: Co-investigator Dates: October 1, 2017 – September 30, 2018 Direct funds: $50,000 Title: Multi-site Validation and Application of a Consensus DSC-MRI

protocol Source: NIH Role: Co-investigator Dates: 2017 – 2020 Title: The Role of Long Non-coding RNAs in Regulating Histone

Modulated Gene Expression in Glioblastoma Source: Brown University / Ruth Sauber Fellowship Role: Faculty Mentor Dates: 2018 – 2019

Non-Peer Review Title: The Role of Epigenetic versus Genetic Heterogeneity in CNS

Metastasis Source: TGen / USC Role: Co-Investigator Dates: July 1, 2012 - present Title: Role of Two Novel Genes in Bevacizumab Response in Human

Glioblastoma Source: Cleveland Clinic Role: Co-Investigator Dates: March 1, 2012 - present


21

B. Pending Peer Review

Title: Magneto-electric nanoparticle system for dense real-time neuronal stimulation and readout

Source: DARPA Role: Co-investigator Dates: 2017 – 2021 Title: High-quality compact portable low-field head MRI with ultra-fast

gradients Source: NIH Role: Co-investigator Dates: 2017 – 2019 Title: Image-guided non-invasive brain activation with micron and

millisecond resolution Source: NIH Role: Co-investigator Dates: 2017 – 2019 Title: Glioma Cell Migration in Engineered Biomaterial Confinement

Source: NIH Role: Consultant Dates: 2017 - 2019

C. Prior: Peer Review

Title: Development of a novel targeted therapeutic approaches for breast cancer metastasis to brain

Source: Avon Foundation Role: Site Principal Investigator (Primary Institution: Translational Genomics Research Institute) Dates: March 1, 2015 – February 28, 2017 Direct funds: $300,000 Title: Translational Applications of Computational and Mathematical

Neuro-oncology Source: NIH / Loan Repayment Program Role: Research mentor Dates: July 1, 2013 - June 30, 2016 Direct funds: $105,000

Title: Role of Notch Signaling in AVM Development Source: Leslie Munzer Neurological Institute Foundation Role: Principal Investigator, Research Mentor Dates: July 1, 2011 - June 30, 2014


22

Direct Funds: $30,000 (total for all years) Title: Use of Machine Learning and Advanced Analytical Techniques to Improve Operating Room Efficiency Source: IBM Role: Principal Investigator Dates: March 1, 2013- February 28, 2014 Direct Funds: $65,000 (total for all years) Title: Progesterone for the Treatment of Traumatic Brain Injury

(ProTECT™ III) Source: NIH Role: Site Principal Investigator Dates: November 1, 2010 - 2013 Direct Funds: $65,000

Title: The Role of TNF-a and its receptors in the expression of endothelial cell genes. Source: Geisinger Pilot Research Grant Funds Role: Principal Investigator Dates: April 1, 2011 – September 30, 2012 Direct Funds: $5,000 Title: Development of a Quantum Dots Platform for Optical Navigation in

Image-Guided, Minimally Invasive Surgery Source: Department of Defense Telemedicine and Advanced Technology

Research Center (TATRC) Role: Principal Investigator Dates: April 1, 2006 - June 30, 2008 Direct Funds: $183,850 Title: Quantum Dot Based Tumor Localization and Surgical Navigation Source: Cleveland State University Technology Validation Fund Role: Principal Investigator Dates: January 1, 2006 - December 30, 2007 Direct Funds: $150,000 Title: Optical sensor for the in vivo detection of quantum dots Source: CCF Innovation Validation Fund Role: Principal Investigator Dates: April 1, 2005 - March 30, 2006 Direct Funds: $30,650 Title: Therapeutic Studies of Primary CNS Malignancies – NABTT Source: National Cancer Institute Role: Co-Investigator


23

Dates: January 1, 2004 - December 30, 2007 Direct Funds: $278,101 Title: Brain tumor and tumor margin identification using optical

spectroscopy Source: National Institutes of Health Role: Co-Investigator Dates: January 1, 2001 - December 30, 2004 Direct Funds: $1,361,925 Title: Investigation of the role of β2-chimaerin in apoptosis in glioblastoma Source: American Cancer Society, Ohio Division Role: Principal Investigator Dates: August 1, 1995 - December 30, 1996 Direct Funds: $20,530

Title: Correlation of 31P MRS and in vitro invasiveness and proliferation assays of astrocytoma cell lines exposed to tamoxifen,

diphenylhydantoin, and triiodothyronine Source: Cleveland Clinic Foundation Research Projects Committee Role: Principal Investigator Dates: September 1, 1992 - August 30, 1993 Direct Funds: $11,400

Non-Peer Review

Title: Indivumed – Geisinger – Biobanking Cooperative Source: Indivumed Role: Co-investigator Dates: April 1, 2014 – October 1, 2016 Direct Funds: $2,000,000 Title: Effect of NovoTTF-100A™ Together With Temozolomide in Newly

Diagnosed Glioblastoma Multiforme (GBM) Source: Novocure Role: Site Principal Investigator Dates: July 1, 2011 – October 1, 2016 Title: Role of DCVax in Treatment of Newly Diagnosed GBM Source: NW Therapeutics Role: Site Principal Investigator Dates: February 1, 2013 – October 1, 2016 Title: Role of steroid hydrogel in treatment of nocioceptive pain in rodent

model Source: In Vivo Therapeutics Role: Co-investigator Dates: March 1, 2011 – September 30, 2015


24

Direct funds: $150,000

MEDICAL COLLEGE TEACHING ACTIVITIES:

Medical Student Education BROWN UNIVERSITY WARREN ALPERT MEDICAL SCHOOL, Providence, RI Neurosurgery elective clinical rotations 10/2016 - present PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE, Danville, PA Neurosurgery elective clinical rotations 6/2007 – 10/2016 TEMPLE UNIVERSITY SCHOOL OF MEDICINE Neurosurgery elective student rotations 6/2007- 10/2016 CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE Neurosurgery elective student rotations 1/2002- 5/2007 OREGON HEALTH SCIENCES UNIVERSITY SCHOOL OF MEDICINE Neurosurgery elective student rotations 10/2001- 12/2002 VANDERBILT UNIVERSITY SCHOOL OF MEDICINE Neurosurgery elective student rotations 7/1998 - 9/2001 Resident & Fellow Education LIFESPAN HEALTH SYSTEM Brain Tumor Board weekly conference 10/2016 - present Monday neurosurgery grand rounds 10/2016 - present Epilepsy monthly conference 10/2016 - present Spinal surgery conference 10/2016 - present GEISINGER HEALTH SYSTEM Brain Tumor Board weekly conference 6/2007 - 10/2016 Friday neurosurgery teaching conference 9/2007 - 10/2016 Epilepsy weekly conference 1/2008 – 10/2016 Spinal surgery indications conference 9/2009 – 10/2016 Continuing Medical Education (Symposia Developed or Chaired) Cleveland Clinic Neuro-Oncology Update 1/2006 Geisinger Brain Tumor Board 6/2007 – 10/2016 Spinal Surgery Indications Conference 9/2009 - 10/2016 Neuro-Oncology and Skull Base Surgery, 1st Geisinger Annual Neurosurgery CME, Philadelphia, PA, 11/2011 Endovascular and Neurovascular Surgery, 2nd Geisinger Annual Neurosurgery CME, NY, NY, 11/2012 Comparative Effectiveness Research in the Neurosciences, 3rd Geisinger Annual Neurosurgery CME, Washington, DC 11/2013


25

Community/Lay Public “Treatment of Brain Tumor” WEWS News Interview, Cleveland, Ohio, 11/2005 “Amazing Lives – Rewire My Brain – Man Has a Massive Tumor Growing Deep

Inside his Brain”, BBC / Discovery Channel Documentary 12/2005 Cleveland Clinic Brain Tumor Patient Education Conference, 9/2005, 9/2006 Geisinger Brain Tumor Support Group 1/2010 – 10/2016 “Meet the Doctor”, WVIA Roundtable Interview, Wilkes Barre, PA 1/2014 “Targeting MEK as a Treatment Strategy for CNS Metastasis”, OncLive TV 11/2014 “NovoTTF and Temozolomide for Glioblastoma” 11/2014 “Tumor treating fields and temozolomide for newly diagnosed glioblastoma” 9/2015

EXTRAMURAL TEACHING Visiting Professor, Alleghany General Hospital, Pittsburgh, PA Dept. of Neurosurgery 5/2012 Visiting Professor, University of Rochester, Rochester, NY Dept. of Neurological Surgery 5/2013 Visiting Professor, Inova Hospital System, Fairfax, VA, Dept. of Neurosurgery 10/2015 Visiting Professor, Rhode Island Hospital, Brown University, Dept. of Neurosurgery 5/2016 STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:

Medical Students Victoria Ebiana 6/2006 – 9/2006 Matthew Gasteiger 4/2013 – 8/2014 David Karambizi 11/2016 - present Catherine Garcia 1/2017 - present Oliver Tang 4/2018 – present Krissia Rivera-Perla 4/2018 - present

Research Fellows Heather Jackson, BS 4/2005 – 9/2006 Madalina Popescu, MD 9/2006 – 6/2007 Weisheng Wang, MD 10/2006 – 5/2007 Anca Dumitrea, MD 11/2007 – 6/2009 Ion Dan Grosu, MD 6/2009 – 6/2010 Alex Selaru, MD 6-2012 – 6/2013

Clinical Fellows

Lily Angelov, MD 01/2003 - 06/2004 Clinical Brain Tumor Fellow Tina Thomas, MD 07/2005 - 06/2006 Clinical Brain Tumor Fellow Maleeha Ahmad, MD 09/2015 – 10/2016 Neurosurgical Oncology Fellow Mayur Jayarao, MD 07/2017 – 12/2017 Neurosurgical Oncology Fellow

Residents Farhad Limonadi, MD 1/2002 - 12/2002 VA resident clinical mentor Vitaly Siomin, MD 1/2004 - 5/2005 Resident research mentor Kara Beasley, DO 1/2008 - 6/2009 Resident research mentor Mark Rivkin, DO 4/2011 – 6/2014 Resident research mentor Bryan Bollinger, DO 4/2010 – 6/2013 Resident research mentor Konstantina Svokos, DO 9/2013 - 12/2014 Resident research mentor Jesna Sublett, MD 7/2015 – 10/2016 Resident research mentor


26

Faculty

Robert Weil, MD 7/1999 - 9/2001 Clinical Mentor Amir Dehdashti, MD 3/2008 - 7/2013 Research mentor Nick Marko, MD 7/2013 – 10/2016 Research mentor EXTRAMURAL STUDENTS. FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED: Maheela Ahmad, MBBS 7/2012 – 6/2015 Research fellow Kris Kimmels, MD 4/2013 – 5/2015 Research fellow PROGRAMMATIC DEVELOPMENTS Educational Programs Student 1. Philadelphia College of Osteopathic Medicine Neurosurgery rotations: 6/2007 – 10/2016 2. Temple University School of Medicine Clinical Neurosurgery rotations: 6/2007 - 10/2016 Resident 1. Neurosurgery Physician’s Assistant Residency Program: One of only two programs currently available in the United States to offer advanced training for PAs, NPs, and other advanced practitioners. The residency consists of 6 months of didactics and related field rotations and 6 months of practical hands on experience in clinical neurosurgery rotations. 2. Neurology Residency Program: A fully ACGME accredited neurology program at Geisinger Health System which began 7/2012. Four residents per year are trained in community and subspecialty neurology with a focus on clinical effectiveness research hosted at the Geisinger Medical Center and under the direction of Jonathan Hosey, MD, FAAN. 3. Neurosurgery Residency Program: A fully ACGME accredited neurosurgery residency program at Geisinger Health System which began 07/2013. The program is a 7 years of training in subspecialty neurosurgery with one year of clinical or laboratory research at Geisinger Medical Center and Geisinger Wyoming Valley developed under the direction of Shelly Timmons, MD, PhD, FACS, FAANS. Fellow 1. Geisinger Health System Surgical Neuro-oncology Fellowship: This is a one to two year program in neurosurgical oncology which develops advanced clinical and research training in basic science and clinical / translational research in topics related to brain and spinal tumor care. The first fellow entered 9/2015. 2. Lifespan Health System / Brown University Surgical Neuro-oncology Fellowship: This is a one to two year program in neurosurgical oncology which develops advanced clinical and research training in basic science and clinical / translational research in topics related to brain and spinal tumor care. The first fellow is anticipated 7/2015.


27

Research Programs Established CCF Tumor Brain Bank 9/1995 Established Vanderbilt Brain Tumor Bank 10/1998 Established Geisinger Brain Tumor Bank 9/2007 Developed Optics/Nanotechnology Lab, The Cleveland Clinic Brain Tumor Institute 1/2002 Developed Molecular Neurosurgery Lab, Geisinger Health System 1/2011 Developed Geisinger High Performance Computing Center, Geisinger Health System 4/2013 Co-Director, Molecular Neuroscience and Neuro-oncology Laboratories, Lifespan Health System 10/2017 Clinical Programs Vanderbilt Skull Base Surgery Team 7/1998 Cleveland Clinic BTI Center for Metastatic Disease 1/2002 Developed Geisinger Neuroscience Institute 6/2007 Community Programs Geisinger Brain Tumor Support Group 1/2010 PATENTS AND PATENT APPLICATIONS 1. U.S. Patent Grant 6,377,841, filed April 23, 2002: Tumor demarcation using optical spectroscopy. Lin WC, Mahadevan-Jansen A, Jansen ED, and Toms SA.

2. U.S. Patent Application 10/360776, filed March 4, 2004: Identification of human tissue using optical spectroscopy. Lin WC, Toms S,Mahadevan-Jansen Phillips P, Johnson M, Weil RA.

3. U.S. Patent Application 10/613225, filed July 3, 2003: Apparatus and methods of detection of radiation injury using optical spectroscopy. Lin WC, Mahadevan-Jansen A, Jansen ED, and Toms SA.

4. U.S. Patent Application 13/116994, filed May 26, 2011: Apparatus and methods for radiofrequency ablation of a liver tumor in liver tissues. Lin WC, Toms SA, Mahadevan-Jansen A, and Chari RS.

5. U.S. Patent Application 12/537008, filed August 6, 2009: System and methods for differentiation of normal and malignant in vivo liver tissues. Lin WC, Toms SA, Mahadevan-Jansen A, and Chari RS.

6. U.S. Patent Application 04/032055, filed Sept. 30, 2004: Method and apparatus for optical spectroscopic detection of cell and tissue. Chari RS, Mahadevan-Jansen A, Toms SA, and Lin WC.

7. U.S. Patent Application 05/036427 filed October 7, 2005: Medical imaging using quantum Dots. Toms SA, Lin WC.

Steven A. Toms, M.D., M.P.H., F.A.A.N.S., F.A.C.S. · 10/4/2018 · Steven A. Toms, MD, MPH,...

Documents

Transcript of Steven A. Toms, M.D., M.P.H., F.A.A.N.S., F.A.C.S. · 10/4/2018 · Steven A. Toms, MD, MPH,...